These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25967144)

  • 1. Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.
    Reed CM; Cresce ND; Mauldin IS; Slingluff CL; Olson WC
    Clin Cancer Res; 2015 Sep; 21(17):3879-87. PubMed ID: 25967144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
    J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of helper peptide vaccination for metastatic melanoma.
    Hu Y; Kim H; Blackwell CM; Slingluff CL
    Ann Surg; 2015 Sep; 262(3):456-64; discussion 462-4. PubMed ID: 26258314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
    Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
    Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
    Hu Y; Petroni GR; Olson WC; Czarkowski A; Smolkin ME; Grosh WW; Chianese-Bullock KA; Slingluff CL
    Cancer Immunol Immunother; 2014 Aug; 63(8):779-86. PubMed ID: 24756419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
    Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L
    Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
    Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE
    Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
    Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
    J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
    Noguchi M; Mine T; Yamada A; Obata Y; Yoshida K; Mizoguchi J; Harada M; Suekane S; Itoh K; Matsuoka K
    Oncol Res; 2007; 16(7):341-9. PubMed ID: 17518272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
    Vavolizza RD; Petroni GR; Mauldin IS; Chianese-Bullock KA; Olson WC; Smith KT; Dengel LT; Haden K; Grosh WW; Kaur V; Varhegyi N; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
    Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
    Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
    Køllgaard T; Ugurel-Becker S; Idorn M; Andersen MH; Becker JC; Straten PT
    PLoS One; 2015; 10(7):e0131934. PubMed ID: 26176858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine.
    Matsueda S; Shichijo S; Nagata S; Seki C; Yamada A; Noguchi M; Itoh K
    Cancer Sci; 2015 Nov; 106(11):1493-8. PubMed ID: 26331453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.